Procaps (PROC) - Market Value

The asset value of Procaps Group S.A. (PROC), currently at 0.11 as shown on the chart, is based on the company's leadership in softgel production in Latin America and its pricing power over industry behemoths. The business relies on an autonomous development cycle, making it resilient to global crises and a reliable defensive asset. High trust from global partners is ensured by the impeccable quality of its contract manufacturing.

Procaps - PROC Market Valuation (period 07/04/2022 - 02/16/2025)

Comprehensive metric breakdowns and analytics for Procaps Group Corp (PROC)

- market price and analyst price targets:

Price Chart Procaps|PROC - Fair Value Consensus

- market capitalization indicators:

Market Value Procaps Group Corp|PROC - Total Enterprise Value

- book value of equity indicators:

Book Value per Share Procaps|PROC - Company Net Assets|Market Value to Book Value Ratio procapsgroup.com|PROC - Total Asset Value of Company

- debt and liquidity data:

- financial results and valuation multiples details:

PROC - Net Profit|Future Profit Procaps Group S.A.|PROC - Company Value to Net Income|Future Price to Earnings Procaps Group SA|PROC - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Procaps Group Corp|PROC - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Procaps|PROC - Earnings per share for the trailing year|Quarterly EPS earnings growth procapsgroup.com|PROC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Procaps Group S.A.

Fundamental company analysis:PROC (Procaps)

Investors are seeking fundamental benchmarks in the financial statements of Procaps Group S.A. (PROC) to assess business value. Market capitalization measures the total value of all shares, reflecting current market demand for the assets. Analyzing the issuer's aggregate market value allows for the real-time tracking of price fluctuations between quarterly reports. The robotization of pharmaceutical plants reduces operating expenses, directly impacting investment attractiveness. The stability of the curve confirms the efficiency of automated production.

Key competitors